JPWO2020154534A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020154534A5
JPWO2020154534A5 JP2021543207A JP2021543207A JPWO2020154534A5 JP WO2020154534 A5 JPWO2020154534 A5 JP WO2020154534A5 JP 2021543207 A JP2021543207 A JP 2021543207A JP 2021543207 A JP2021543207 A JP 2021543207A JP WO2020154534 A5 JPWO2020154534 A5 JP WO2020154534A5
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
once
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523680A5 (https=
JP7675014B2 (ja
JP2022523680A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014836 external-priority patent/WO2020154534A1/en
Publication of JP2022523680A publication Critical patent/JP2022523680A/ja
Publication of JP2022523680A5 publication Critical patent/JP2022523680A5/ja
Publication of JPWO2020154534A5 publication Critical patent/JPWO2020154534A5/ja
Priority to JP2025072923A priority Critical patent/JP2025118706A/ja
Application granted granted Critical
Publication of JP7675014B2 publication Critical patent/JP7675014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543207A 2019-01-23 2020-01-23 Ｂ細胞免疫療法 Active JP7675014B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072923A JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962795629P 2019-01-23 2019-01-23
US62/795,629 2019-01-23
US201962837765P 2019-04-24 2019-04-24
US62/837,765 2019-04-24
US202062965032P 2020-01-23 2020-01-23
PCT/US2020/014836 WO2020154534A1 (en) 2019-01-23 2020-01-23 B cell immunotherapy
US62/965,032 2020-01-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072923A Division JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Publications (4)

Publication Number Publication Date
JP2022523680A JP2022523680A (ja) 2022-04-26
JP2022523680A5 JP2022523680A5 (https=) 2023-02-01
JPWO2020154534A5 true JPWO2020154534A5 (https=) 2023-02-01
JP7675014B2 JP7675014B2 (ja) 2025-05-12

Family

ID=71735798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543207A Active JP7675014B2 (ja) 2019-01-23 2020-01-23 Ｂ細胞免疫療法
JP2025072923A Pending JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072923A Pending JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Country Status (4)

Country Link
US (1) US20220079986A1 (https=)
JP (2) JP7675014B2 (https=)
CA (1) CA3127623A1 (https=)
WO (1) WO2020154534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4236968A4 (en) * 2020-10-30 2024-03-27 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
JP2024543827A (ja) * 2021-11-11 2024-11-26 ザ ジェネラル ホスピタル コーポレイション 筋萎縮性側索硬化症のステージおよび進行を画定するための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555457C (en) * 2004-02-09 2012-08-21 Mitsubishi Pharma Corporation A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
WO2006119170A2 (en) * 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
CA2722184A1 (en) * 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
EP2576772B1 (en) * 2010-05-26 2018-12-12 Deutsches Rheuma-Forschungszentrum Berlin Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells
US20140079675A1 (en) * 2011-04-04 2014-03-20 HumaCell, Inc. Repair of Neurodegenerative Diseases
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease

Similar Documents

Publication Publication Date Title
Jiang et al. Ischemic stroke: From pathological mechanisms to neuroprotective strategies
Sfikakis et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti–tumor necrosis factor monoclonal antibody infliximab
Liu et al. The roles of Th cells in myocardial infarction
JP2025118706A5 (https=)
JP2026035701A5 (https=)
Tappeiner et al. Rituximab as a treatment option for refractory endogenous anterior uveitis
Huang et al. Early methylprednisolone treatment can stabilize the blood-optic nerve barrier in a rat model of anterior ischemic optic neuropathy (rAION)
Kanda et al. Interferon-lnduced Sudden Hearing Loss
JP2004508280A5 (https=)
Yin et al. Ramsay Hunt syndrome and mandibular alveolar bone necrosis following herpes zoster: A case report and literature review
JPWO2020154534A5 (https=)
DE69001686T2 (de) Behandlung von leukozytstoerungen mit gm-csf.
Graybill et al. R 51211 (itraconazole) therapy of murine cryptococcosis
Mitra et al. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia
Spink et al. Persistent menace of pneumococcal meningitis
JP2021520353A5 (https=)
JP2021518392A5 (https=)
JP2005529152A5 (https=)
Banks The blood brain barrier
Yang et al. Interferon-alpha in the management of patients with Behcet's disease
CN114288314A (zh) 克拉屈滨在制备用于预防或治疗银屑病药物中的用途
JP2023524111A (ja) サイトカインストームを治療するための組成物および方法
JPH04500210A (ja) 後天性免疫不全に関係した骨髄抑止の治療
US20250002559A1 (en) Pharmaceutical formulation for treatment of cerebral stroke
Kang et al. Mucosal deposit after triamcinolone injection: a case report